Investing to Find Cures for Cancer

Juno’s pipeline of therapeutic T cell product candidates apply our CAR and TCR technologies against a variety of cancer targets.

Juno Therapeutics Current Pipeline

ALL=acute lymphoblastic leukemia; AML=acute myeloid leukemia; CLL=chronic lymphocytic leukemia; NHL=non-Hodgkin lymphoma; NSCLC=non-small cell lung cancer

Our-Science

Clinical

Juno’s CD19 CAR and WT-1 TCR clinical programs include multiple product candidates in clinical development for several hematologic malignancies in adults and children.

Pre-Clinical

Juno is investing in continued technology improvements as well as CAR and TCR product candidates targeting multiple cancer types.

Therapeutic Areas

Juno is developing cell-based therapies across various cancer types and understanding the technology’s application to other diseases.